Chemical Structure (F205834f 7a27 4968 9605 90a2c53ce7e9 01)
Losartan Potassium Tablet
Product Images NDC 72162-2506
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72162-2506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (F205834f 7a27 4968 9605 90a2c53ce7e9 02)
This text provides data on the percentage of patients who reached the primary endpoint in a clinical trial comparing Atenolol and Losartan potassium. The adjusted risk reduction between the two treatments is reported as 13%, with a significance level of p=0.021. The timeline of the study is also shown with study months marked from 0 to 66.*
Figure 2 (F205834f 7a27 4968 9605 90a2c53ce7e9 03)
This text provides information about two medications, Atenolol and Losarten potassium. The text also mentions an adjusted risk reduction of 25% with a p-value of 0.001. It further highlights the percentage of patients with fatal or non-fatal stroke over different study months.*
Figure 3 (F205834f 7a27 4968 9605 90a2c53ce7e9 04)
This text appears to provide data on a study comparing the effects of Losartan and Atenolol on stroke outcomes in a population with different demographic and medical characteristics. The study includes details like the number of events, rates, and percentages in various subgroups based on age, gender, race, diabetes status, and history of cardiovascular disease. The results seem to suggest that Atenolol may have favored outcomes over Losartan. The analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 (F205834f 7a27 4968 9605 90a2c53ce7e9 05)
This text seems to show the results of a study comparing the effectiveness of Losartan Potassium versus a Placebo in reducing the risk of an event in patients. The study indicates that there was a 16.1% risk reduction with a p-value of 0.022. The data also shows that 9% of the patients with the event were impacted by the intervention.*
Image (F205834f 7a27 4968 9605 90a2c53ce7e9 06)
Company Logo (F205834f 7a27 4968 9605 90a2c53ce7e9 07)
Label (Lbl721622506)
This is a description of a medication package insert for Losartan Potassium tablets, each containing 25 mg of the active ingredient. It provides information on dosage, storage conditions (20° to 25°C), and handling instructions. The package insert includes a QR code for dosage and patient information leaflet. The tablets are to be dispensed by a pharmacist and should be kept out of reach of children. The medication is manufactured by Unichem Laboratories Ltd. and repackaged by Bryant Ranch Prepack, Inc. in the USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
